SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending following news of a multi-year AI compute agreement with OpenAI, including potential stock warrants, leading to significant community discussion about the implications for AMD's market position and future revenue. The collaboration is viewed as a major validation for AMD's technology, with some suggesting it could challenge Nvidia's dominance in the AI chip market. Community members are actively debating the deal's structure and potential impact on AMD's valuation, as well as the broader implications for the AI sector.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin ($APP) is trending due to reports of a SEC probe into its data collection practices, causing a sharp decline in its stock price. The community is debating the severity of the probe, with some viewing it as a buying opportunity and others concerned about potential consequences and overvaluation. Discussions also involve the company's inclusion in the S&P 500 and comparisons to other high-growth tech stocks.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum (QBTS) is trending as community members discuss its potential as a leader in the burgeoning quantum computing sector, drawing comparisons to early NVIDIA and Tesla. Bullish investors highlight the company's existing revenue, enterprise clients, and government contracts as evidence of traction in a field often dismissed as hype. Concerns about valuation persist, with some arguing that traditional metrics fail to capture the disruptive potential of quantum computing and D-Wave's unique position with tested quantum applications.

$4CHAN is a meme token on the Ethereum Network.   4ChanToken represents a global crypto community that pays homage to the memetic powerhouses of the internet as Pepe, Doge, Shib and all major memes inventor combining them all into one super meme token that is $4CHAN. At its core, 4ChanToken embodies the untamed spirit of the notorious 4chan imageboard, where iconic memes are born, nurtured, and unleashed upon the world. With an unyielding spirit of irreverence and a touch of mischief, $4CHAN has emerged as the darling of meme enthusiasts, internet dwellers, and crypto aficionados alike.   The foundation of 4ChanToken lies in its community. We’ve harnessed the chaotic energy of this digital realm to create a currency that celebrates the power of memetic expression, empowering users to engage in a truly unique and decentralized economy. As a passionate supporter, you’ll join a vibrant ecosystem where dank memes and viral sensations are the lifeblood of commerce. 4ChanToken is more than just a digital currency – it’s the place where memes are born.  The ultimate playground for memelords and crypto degens. Based on the simplicity of holdrs/volume operating a store of value.  The identification of this value is best described as 'digital gold'. That $4chan can ultimately represent a superior store of value relative to all other forms of memecoins by embodying all memes in one token as the factual birthplace of all popular memes.

4Chan

4Chan is trending as community members discuss its potential as the 'Bitcoin of memecoins' and its strong community. Some users highlight the large number of zeros in its price, while others express excitement about potential gains and compare it to other popular meme coins like $PEPE and $HONK. The community also seems focused on holding for the long term, anticipating a significant increase in market cap.

Spruce Biosciences, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.

Spruce Biosciences Inc

SPRB is trending due to a significant surge following FDA Breakthrough Therapy Designation for its Sanfilippo syndrome type B treatment, with the community actively discussing the potential for a gamma squeeze and comparing it to other high-flying stocks. Some traders are wary of a potential pullback or secondary offering, while others speculate about further upside and long-term prospects given the small float. The conversation also includes comparisons to other companies and discussions on potential short squeezes.

Society Pass, Inc. engages in the operation and acquisition of fintech and e-commerce platforms and mobile applications. It operates through the following segments: Online Food and Beverage (F&B) and Groceries Deliveries, Digital Marketing, Online Ticketing and Reservation, e-Commerce, Telecommunication Reseller, and Merchant Point of Sale (POS). The Online F&B and Groceries Deliveries segment includes the operation of Handycart, Mangan, and Pushkart brands. The Digital Marketing segment involves the engagement with creators and management of platforms. The Online Ticketing and Reservation segment focuses on the sale of domestic and overseas air ticket and global hotel reservations. The e-Commerce segment refers to the operation of an online lifestyle platform under the brand name Leflair. The Telecommunication Reseller segment consists of sales of local mobile phone plans and global internet data provider plans. The Merchant POS segment covers the sale of hardware and software. The company was founded by Luan Thuc Nguyen on June 22, 2018 and is headquartered in Carson City, NV.

Society Pass Inc

Society Pass is trending as traders discuss its potential for significant upward movement, drawing comparisons to other high-flying stocks. The community is focused on technical analysis, potential short squeezes, and a recently raised price target from Ascendiant Capital. Some are citing the company's underlying value and upcoming subsidiary IPOs as reasons for optimism.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health ($OSCR) is trending amid speculation around the potential extension of ACA subsidies, with community members actively discussing its positive implications for the insurer. Talk centers on the potential for enrollment growth and reduced premium risks should the subsidies be maintained. Some traders anticipate a year-end rally, while others debate fair valuation and short squeeze potential.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending amid discussions about its partnerships with AI leaders like Nvidia and OpenAI, with some seeing it as undervalued relative to peers. The community is debating whether the recent price action reflects its potential in the agentic AI space, with some citing CEO stock sales as a concern. Bullish investors are pointing to strong fundamentals and potential for a breakout, while others remain cautious.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending amid speculation of a potential tie-up with Tesla, fueled by a recent video featuring Archer's eVTOL alongside Tesla's Optimus robot. The community is actively discussing the possibility of a partnership announcement and its impact on the stock. Some believe this collaboration could revolutionize air mobility, while others urge caution due to regulatory challenges and the lack of official confirmation.

Doodles is a next-generation entertainment company focused on immersive storytelling through the creation and distribution of live and digital experiences, original content, and lifestyle products.  Doodles mission is to define the standard for immersive storytelling and color the world with joy.

Doodle Inu

Doodle Inu ($DOOD) is trending amid community excitement, with some suggesting it could be the next big meme coin in the dog-themed crypto space, drawing comparisons to $SHIB and $DOGE. The community is closely watching key price levels, anticipating a breakout and significant gains, while also highlighting a recent callout from a crypto influencer.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of GT Biopharma, Inc. surged more than 21% on Tuesday before slipping after-hours as investors reacted to the company's unexpected shift in its financing strategy.&nbsp;The announcement sent 24-hour message volume on Stocktwits skyrocketing by 18,700%, marking the highest spike among biotech stocks, with trading volume more than doubling from its daily average.The company said it had withdrawn its earlier Form S-1 registration, initially filed with the SEC in December, which sought approval for an automatic mixed securities shelf offering.&nbsp;The filing had not yet been declared effective, and no securities had been sold under the proposed offering.&nbsp;Instead, GT Biopharma opted for a direct warrant exercise agreement, securing immediate funds while offering new unregistered warrants to investors.Under the new arrangement, the company entered into definitive agreements to exercise existing warrants to purchase 302,069 shares of common stock, with an exercise price of $4.35 per share.&nbsp;The move is expected to generate approximately $700,000 in gross proceeds before deducting placement agent fees and offering expenses.The offering is anticipated to close by Thursday, with proceeds earmarked for working capital and general corporate purposes.On Stocktwits, retail investors' reactions were mostly positive to the company's financing shift.&nbsp;One user described the move as "going in the right direction."&nbsp;<stembedurl>https://stocktwits.com/Rassy40/message/605686808</stembedurl>Another pointed out that short sellers had expected dilution due to the S-1 registration, but they may now be forced to cover with the offering canceled.&nbsp;<stembedurl>https://stocktwits.com/Annet_why_net/message/605691704</stembedurl>However, some traders indicated they were still waiting for a more attractive entry point.Short interest on GTBP shares has jumped from 0.6% at the start of the year to 8.8% at the end of last week, per Koyfin data.Beyond the financing development, Roth MKM remains optimistic about GT Biopharma's clinical pipeline.&nbsp;The research firm expects the company to release initial data later this year from its Phase 1 trial evaluating GTB-3650, its therapy targeting CD33-expressing hematologic malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome.GT Biopharma ended 2024 with approximately $4 million in cash, which Roth MKM estimates is sufficient to fund operations into the second quarter of this year.&nbsp;The research firm maintained a 'Buy' rating on the stock, with an $11 price target, implying a potential fivefold increase from current levels.The company's stock has lost more than 17% year-to-date.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

GT Biopharma Retail Chatter Soars Most Among Biotechs After Financing Strategy Tweak

The company said it had withdrawn its earlier Form S-1 registration, initially filed with the SEC in December, which sought approval for an automatic mixed securities shelf offering.

Equity

The company said it had withdrawn its earlier Form S-1 registration, initially filed with the SEC in December, which sought approval for an automatic mixed securities shelf offering.


Recap: GT Biopharma Q4 Earnings

GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results

Remain in active dialogue with the FDA regarding IND clearance for GTB-3650, a 2nd generation nanobody TriKE for treatment of CD33+ leukemiaPhase 1 trial with GTB-3650 anticipated to start in 2H...

GT Biopharma trading halted, news pending

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

GT Biopharma announces 1-for-30 reverse stock split

GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split

BRISBANE, CALIFORNIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP) (the Company ), a clinical stage immuno-oncology company focused on developing innovative therapeutics...

Short Interest in GT Biopharma, Inc. (NASDAQ:GTBP) Expands By 150.2%

GT Biopharma, Inc. (NASDAQ:GTBP  Get Free Report) was the target of a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 58,800...

GT Biopharma (NASDAQ:GTBP) & PaxMedica (NASDAQ:PXMD) Critical Survey

GT Biopharma (NASDAQ:GTBP  Get Free Report) and PaxMedica (NASDAQ:PXMD  Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the...

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). Its product, GTB-3550, is initially developed for the treatment of AML and MDS, and other CD33+ hematologic cancers. GT Biopharma has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. The company was founded in 1965 and is headquartered in San Francisco, CA.

GT Biopharma Inc

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

Current Price	$0.7062
Prev Close	$0.6386
Open	$0.70
Dividend Yield	0.00%
50-Day Moving Average	$1.15
Beta	0.69
Avg. Volume	625,755.52
PE Ratio	-0.17

52-Week High	$4.10
52-Week Low	$0.55
Market Capitalization	$2.51M
EPS (Annual)	-$6.94
Price to Book	0.81
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

GTBP
GT Biopharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GTBP News

GTBP GT Biopharma Inc